Supriya Lifescience Q2 FY26 Concall Decoded: – 20% growth comeback, China exits, and a ₹1,000 crore dream that refuses to die
1. Opening Hook
After a Q1 that looked like a chemistry experiment gone wrong, Supriya Lifescience returned in Q2 claiming, “Relax, that was just a lab shutdown.” Revenue bounced back, margins stayed smug, and management sounded like they never doubted themselves for a second. Apparently, Q1 was an “aberration,” not a warning—because when you run a regulated export-heavy API business, excuses are also GMP-certified.
Exports are still king, China is the villain, and Ambernath is the shiny new toy everyone is waiting to unwrap. The company says it’s “back on track,” analysts nodded politely, and nobody dared ask why Q1 had to happen in the first place.
Stick around—because the real story hides in CDMO dreams, delayed filings, and a ₹1,000 crore target that management swears is inevitable. Things get spicy later.
2. At a Glance
Revenue ₹200 cr (+20% YoY) – Q1 who? Management pretends it never existed.
EBITDA ₹73 cr (+12% YoY) – Grew, but not as fast as confidence levels.
EBITDA margin 36% – Right on guidance, no margin gymnastics required.
PAT ₹50 cr (+9% YoY) – Profits showed up, slightly late but acceptable.
Exports at 81% – Domestic market still ignored like spam mail.
Backward integration at 79% – Because buying raw materials is for amateurs.
3. Management’s Key Commentary
“Q1 was an aberration, and we are back on track with 20% sales growth.” (Translation: Please stop asking about Q1 😏)
